About Pricing FAQs Providers Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

TERMINATEDPhase 2NCT01039103

Nanocort in Acute Exacerbation of Relapsing-Remitting Multiple Sclerosis (MS)

Patients with an acute exacerbation of Relapsing-Remitting Multiple Sclerosis or with Clinically Isolated Syndrome receive either one single infusion of Nanocort or three daily infusions of SoluMedrol...

Lead sponsor: Galapagos NV•8 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Galapagos NV

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Diagnosis of RRMS (per McDonald criteria, 2005) with dissemination in time and space OR a diagnosis of CIS confirmed by MRI. Patients with CIS who only have optic neuritis will be excluded from this study
•A maximum Expanded Disability Status Scale (EDSS) score of ≤ 6
•New neurological symptoms or exacerbation of prior neurological symptoms of over 24 hours duration but \<7 days duration, verified by neurological examination

Exclusion Criteria

•Primary progressive MS.
•Secondary progressive MS without superimposed relapses.
•Received systemic corticosteroids within 4 weeks of screening for treatment of MS or other conditions.
•any contraindication for treatment with (systemic) corticosteroids

Related studies

Autoimmune Intervention Mastery Course Study

NCT05057676 · Multiple Sclerosis, Clinically Isolated Syndrome, and more

Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis

NCT04798651 · Multiple Sclerosis, Clinically Isolated Syndrome

RECRUITINGPhase 2

Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation (AttackMS)

NCT05418010 · Multiple Sclerosis, Clinically Isolated Syndrome of Demyelination

Predictive Value of the Optic Nerve Involvement in Clinically Isolated Syndrome

NCT06455332 · Clinically Isolated Syndrome, Multiple Sclerosis

Pregnancy Cohort in Multiple Sclerosis (MS)

NCT05010902 · Multiple Sclerosis (MS), Clinically Isolated Syndrome (CIS)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: October 6, 2016Terms

Trial snapshot

StatusTERMINATED

PhasePHASE2

Enrollment15

Start dateDec 2009

Last updatedOct 6, 2016

Condition

Acute Exacerbation of Remitting Relapsing Multiple Sclerosis Clinically Isolated Syndrome

Locations shown

Departement Neurologie AZ St Jan AV

Bruges

Nationaal MS Centrum

Melsbroek

Revalidatie & MS-centrum Overpelt

Overpelt

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 6, 2016Data synced to Clareo: July 13, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions